Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Effectiveness of single dose rifampicin after BCG-vaccination to prevent leprosy in close contacts of patients with newly diagnosed leprosy: a cluster randomized controlled trial.

Richardus R, Alam K, Kundu K, Chandra Roy J, Zafar T, Chowdhury AS, Nieboer D, Faber R, Butlin CR, Geluk A, Richardus JH.

Int J Infect Dis. 2019 Sep 6. pii: S1201-9712(19)30365-0. doi: 10.1016/j.ijid.2019.08.035. [Epub ahead of print]

PMID:
31499206
2.

Archival, paleopathological and aDNA-based techniques in leprosy research and the case of Father Petrus Donders at the Leprosarium 'Batavia', Suriname.

Van Dissel JT, Pieters T, Geluk A, Maat G, Menke HE, Tió-Coma M, Altena E, Laros JFJ, Adhin MR.

Int J Paleopathol. 2019 Aug 17;27:1-8. doi: 10.1016/j.ijpp.2019.08.001. [Epub ahead of print]

PMID:
31430635
3.

Application of new host biomarker profiles in quantitative point-of-care tests facilitates leprosy diagnosis in the field.

van Hooij A, van den Eeden S, Richardus R, Tjon Kon Fat E, Wilson L, Franken KLMC, Faber R, Khatun M, Alam K, Sufian Chowdhury A, Richardus JH, Corstjens P, Geluk A.

EBioMedicine. 2019 Aug 14. pii: S2352-3964(19)30526-2. doi: 10.1016/j.ebiom.2019.08.009. [Epub ahead of print]

4.

Detection of Mycobacterium leprae DNA in soil: multiple needles in the haystack.

Tió-Coma M, Wijnands T, Pierneef L, Schilling AK, Alam K, Roy JC, Faber WR, Menke H, Pieters T, Stevenson K, Richardus JH, Geluk A.

Sci Rep. 2019 Feb 28;9(1):3165. doi: 10.1038/s41598-019-39746-6.

5.

Fingerstick test quantifying humoral and cellular biomarkers indicative for M. leprae infection.

Corstjens PLAM, van Hooij A, Tjon Kon Fat EM, Alam K, Vrolijk LB, Dlamini S, da Silva MB, Spencer JS, Salgado CG, Richardus JH, van Hees CLM, Geluk A.

Clin Biochem. 2019 Apr;66:76-82. doi: 10.1016/j.clinbiochem.2019.01.007. Epub 2019 Jan 26.

6.

Evaluation of Immunodiagnostic Tests for Leprosy in Brazil, China and Ethiopia.

van Hooij A, Tjon Kon Fat EM, Batista da Silva M, Carvalho Bouth R, Cunha Messias AC, Gobbo AR, Lema T, Bobosha K, Li J, Weng X, Salgado CG, Spencer JS, Corstjens PLAM, Geluk A.

Sci Rep. 2018 Dec 18;8(1):17920. doi: 10.1038/s41598-018-36323-1.

7.

Complement Component C1q as Serum Biomarker to Detect Active Tuberculosis.

Lubbers R, Sutherland JS, Goletti D, de Paus RA, van Moorsel CHM, Veltkamp M, Vestjens SMT, Bos WJW, Petrone L, Del Nonno F, Bajema IM, Dijkman K, Verreck FAW, Walzl G, Gelderman KA, Groeneveld GH, Geluk A, Ottenhoff THM, Joosten SA, Trouw LA.

Front Immunol. 2018 Oct 23;9:2427. doi: 10.3389/fimmu.2018.02427. eCollection 2018.

8.

Evidence of zoonotic leprosy in Pará, Brazilian Amazon, and risks associated with human contact or consumption of armadillos.

da Silva MB, Portela JM, Li W, Jackson M, Gonzalez-Juarrero M, Hidalgo AS, Belisle JT, Bouth RC, Gobbo AR, Barreto JG, Minervino AHH, Cole ST, Avanzi C, Busso P, Frade MAC, Geluk A, Salgado CG, Spencer JS.

PLoS Negl Trop Dis. 2018 Jun 28;12(6):e0006532. doi: 10.1371/journal.pntd.0006532. eCollection 2018 Jun.

9.

Correlates of immune exacerbations in leprosy.

Geluk A.

Semin Immunol. 2018 Oct;39:111-118. doi: 10.1016/j.smim.2018.06.003. Epub 2018 Jun 24. Review.

10.

Minimum requirements and optimal testing strategies of a diagnostic test for leprosy as a tool towards zero transmission: A modeling study.

Blok DJ, de Vlas SJ, Geluk A, Richardus JH.

PLoS Negl Trop Dis. 2018 May 25;12(5):e0006529. doi: 10.1371/journal.pntd.0006529. eCollection 2018 May.

11.

BCG and Adverse Events in the Context of Leprosy.

Richardus R, van Hooij A, van den Eeden SJF, Wilson L, Alam K, Richardus JH, Geluk A.

Front Immunol. 2018 Apr 4;9:629. doi: 10.3389/fimmu.2018.00629. eCollection 2018.

12.

Vaccines for Leprosy and Tuberculosis: Opportunities for Shared Research, Development, and Application.

Coppola M, van den Eeden SJF, Robbins N, Wilson L, Franken KLMC, Adams LB, Gillis TP, Ottenhoff THM, Geluk A.

Front Immunol. 2018 Feb 26;9:308. doi: 10.3389/fimmu.2018.00308. eCollection 2018. Review.

13.

Africa-wide evaluation of host biomarkers in QuantiFERON supernatants for the diagnosis of pulmonary tuberculosis.

Chegou NN, Sutherland JS, Namuganga AR, Corstjens PL, Geluk A, Gebremichael G, Mendy J, Malherbe S, Stanley K, van der Spuy GD, Kriel M, Loxton AG, Kriel B, Simukonda F, Bekele Y, Sheehama JA, Nelongo J, van der Vyver M, Gebrexabher A, Hailu H, Esterhuyse MM, Rosenkrands I, Aagard C, Kidd M, Kassa D, Mihret A, Howe R, Cliff JM, Crampin AC, Mayanja-Kizza H, Kaufmann SHE, Dockrell HM, Ottenhoff THM, Walzl G; AE-TBC consortium.

Sci Rep. 2018 Feb 8;8(1):2675. doi: 10.1038/s41598-018-20855-7.

14.

Longitudinal assessment of anti-PGL-I serology in contacts of leprosy patients in Bangladesh.

Richardus RA, van der Zwet K, van Hooij A, Wilson L, Oskam L, Faber R, van den Eeden SJF, Pahan D, Alam K, Richardus JH, Geluk A.

PLoS Negl Trop Dis. 2017 Dec 11;11(12):e0006083. doi: 10.1371/journal.pntd.0006083. eCollection 2017 Dec.

15.

Opening a Can of Worms: Leprosy Reactions and Complicit Soil-Transmitted Helminths.

Hagge DA, Parajuli P, Kunwar CB, Rana DRSJB, Thapa R, Neupane KD, Nicholls P, Adams LB, Geluk A, Shah M, Napit IB.

EBioMedicine. 2017 Sep;23:119-124. doi: 10.1016/j.ebiom.2017.08.026. Epub 2017 Sep 1.

16.

CRP: tell-tale biomarker or common denominator?

Geluk A, Corstjens P.

Lancet Infect Dis. 2017 Dec;17(12):1225-1227. doi: 10.1016/S1473-3099(17)30472-3. Epub 2017 Aug 25. No abstract available.

PMID:
28847637
17.

Field-friendly serological tests for determination of M. leprae-specific antibodies.

van Hooij A, Tjon Kon Fat EM, van den Eeden SJF, Wilson L, Batista da Silva M, Salgado CG, Spencer JS, Corstjens PLAM, Geluk A.

Sci Rep. 2017 Aug 21;7(1):8868. doi: 10.1038/s41598-017-07803-7.

18.

Differences in IgG responses against infection phase related Mycobacterium tuberculosis (Mtb) specific antigens in individuals exposed or not to Mtb correlate with control of TB infection and progression.

Coppola M, Arroyo L, van Meijgaarden KE, Franken KL, Geluk A, Barrera LF, Ottenhoff THM.

Tuberculosis (Edinb). 2017 Sep;106:25-32. doi: 10.1016/j.tube.2017.06.001. Epub 2017 Jun 8.

19.

Longitudinal IP-10 Serum Levels Are Associated with the Course of Disease Activity and Remission in Patients with Rheumatoid Arthritis.

van Hooij A, Boeters DM, Tjon Kon Fat EM, van den Eeden SJF, Corstjens PLAM, van der Helm-van Mil AHM, Geluk A.

Clin Vaccine Immunol. 2017 Aug 4;24(8). pii: e00060-17. doi: 10.1128/CVI.00060-17. Print 2017 Aug.

20.

New Genome-Wide Algorithm Identifies Novel In-Vivo Expressed Mycobacterium Tuberculosis Antigens Inducing Human T-Cell Responses with Classical and Unconventional Cytokine Profiles.

Coppola M, van Meijgaarden KE, Franken KL, Commandeur S, Dolganov G, Kramnik I, Schoolnik GK, Comas I, Lund O, Prins C, van den Eeden SJ, Korsvold GE, Oftung F, Geluk A, Ottenhoff TH.

Sci Rep. 2016 Nov 28;6:37793. doi: 10.1038/srep37793.

21.

Cell-type deconvolution with immune pathways identifies gene networks of host defense and immunopathology in leprosy.

Inkeles MS, Teles RM, Pouldar D, Andrade PR, Madigan CA, Lopez D, Ambrose M, Noursadeghi M, Sarno EN, Rea TH, Ochoa MT, Iruela-Arispe ML, Swindell WR, Ottenhoff TH, Geluk A, Bloom BR, Pellegrini M, Modlin RL.

JCI Insight. 2016 Sep 22;1(15):e88843. doi: 10.1172/jci.insight.88843.

22.

Quantitative lateral flow strip assays as User-Friendly Tools To Detect Biomarker Profiles For Leprosy.

van Hooij A, Tjon Kon Fat EM, Richardus R, van den Eeden SJ, Wilson L, de Dood CJ, Faber R, Alam K, Richardus JH, Corstjens PL, Geluk A.

Sci Rep. 2016 Sep 29;6:34260. doi: 10.1038/srep34260.

23.

Evaluation of cytokine responses against novel Mtb antigens as diagnostic markers for TB disease.

Awoniyi DO, Teuchert A, Sutherland JS, Mayanja-Kizza H, Howe R, Mihret A, Loxton AG, Sheehama J, Kassa D, Crampin AC, Dockrell HM, Kidd M, Rosenkrands I, Geluk A, Ottenhoff TH, Corstjens PL, Chegou NN, Walzl G; AE-TBC Consortium.

J Infect. 2016 Sep;73(3):219-30. doi: 10.1016/j.jinf.2016.04.036. Epub 2016 Jun 14.

24.

Diagnostic performance of a seven-marker serum protein biosignature for the diagnosis of active TB disease in African primary healthcare clinic attendees with signs and symptoms suggestive of TB.

Chegou NN, Sutherland JS, Malherbe S, Crampin AC, Corstjens PL, Geluk A, Mayanja-Kizza H, Loxton AG, van der Spuy G, Stanley K, Kotzé LA, van der Vyver M, Rosenkrands I, Kidd M, van Helden PD, Dockrell HM, Ottenhoff TH, Kaufmann SH, Walzl G; AE-TBC consortium.

Thorax. 2016 Sep;71(9):785-94. doi: 10.1136/thoraxjnl-2015-207999. Epub 2016 May 4.

25.

Field-Friendly Test for Monitoring Multiple Immune Response Markers during Onset and Treatment of Exacerbated Immunity in Leprosy.

Corstjens PLAM, van Hooij A, Tjon Kon Fat EM, van den Eeden SJF, Wilson L, Geluk A.

Clin Vaccine Immunol. 2016 Jun 6;23(6):515-519. doi: 10.1128/CVI.00033-16. Print 2016 Jun.

26.

Exploratory urinary metabolomics of type 1 leprosy reactions.

Mayboroda OA, van Hooij A, Derks R, van den Eeden SJ, Dijkman K, Khadge S, Thapa P, Kunwar CB, Hagge DA, Geluk A.

Int J Infect Dis. 2016 Apr;45:46-52. doi: 10.1016/j.ijid.2016.02.012. Epub 2016 Feb 26.

27.

Leprosy Diagnostic Test Development As a Prerequisite Towards Elimination: Requirements from the User's Perspective.

Roset Bahmanyar E, Smith WC, Brennan P, Cummings R, Duthie M, Richardus JH, Saunderson P, Shwe T, Rosen S, Geluk A.

PLoS Negl Trop Dis. 2016 Feb 11;10(2):e0004331. doi: 10.1371/journal.pntd.0004331. eCollection 2016 Feb. No abstract available.

28.

Use of lateral flow assays to determine IP-10 and CCL4 levels in pleural effusions and whole blood for TB diagnosis.

Sutherland JS, Mendy J, Gindeh A, Walzl G, Togun T, Owolabi O, Donkor S, Ota MO, Kon Fat ET, Ottenhoff TH, Geluk A, Corstjens PL.

Tuberculosis (Edinb). 2016 Jan;96:31-6. doi: 10.1016/j.tube.2015.10.011. Epub 2015 Nov 14.

PMID:
26786652
29.

Complement activation in leprosy: a retrospective study shows elevated circulating terminal complement complex in reactional leprosy.

Bahia El Idrissi N, Hakobyan S, Ramaglia V, Geluk A, Morgan BP, Das PK, Baas F.

Clin Exp Immunol. 2016 Jun;184(3):338-46. doi: 10.1111/cei.12767. Epub 2016 Mar 31.

30.

Longitudinal immune profiles in type 1 leprosy reactions in Bangladesh, Brazil, Ethiopia and Nepal.

Khadge S, Banu S, Bobosha K, van der Ploeg-van Schip JJ, Goulart IM, Thapa P, Kunwar CB, van Meijgaarden KE, van den Eeden SJ, Wilson L, Kabir S, Dey H, Goulart LR, Lobato J, Carvalho W, Bekele Y, Franken KL, Aseffa A, Spencer JS, Oskam L, Otttenhoff TH, Hagge DA, Geluk A.

BMC Infect Dis. 2015 Oct 28;15:477. doi: 10.1186/s12879-015-1128-0.

31.

Multi-center evaluation of a user-friendly lateral flow assay to determine IP-10 and CCL4 levels in blood of TB and non-TB cases in Africa.

Corstjens PL, Tjon Kon Fat EM, de Dood CJ, van der Ploeg-van Schip JJ, Franken KL, Chegou NN, Sutherland JS, Howe R, Mihret A, Kassa D, van der Vyver M, Sheehama J, Simukonda F, Mayanja-Kizza H, Ottenhoff TH, Walzl G, Geluk A; AE-TBC consortium.

Clin Biochem. 2016 Jan;49(1-2):22-31. doi: 10.1016/j.clinbiochem.2015.08.013. Epub 2015 Aug 15.

PMID:
26285074
32.

Synthetic Long Peptide Derived from Mycobacterium tuberculosis Latency Antigen Rv1733c Protects against Tuberculosis.

Coppola M, van den Eeden SJ, Wilson L, Franken KL, Ottenhoff TH, Geluk A.

Clin Vaccine Immunol. 2015 Sep;22(9):1060-9. doi: 10.1128/CVI.00271-15. Epub 2015 Jul 22.

33.

Clinical manifestations of leprosy after BCG vaccination: an observational study in Bangladesh.

Richardus RA, Butlin CR, Alam K, Kundu K, Geluk A, Richardus JH.

Vaccine. 2015 Mar 24;33(13):1562-7. doi: 10.1016/j.vaccine.2015.02.017. Epub 2015 Feb 18.

34.

Differential dermal expression of CCL17 and CCL18 in tuberculoid and lepromatous leprosy.

Berrington WR, Kunwar CB, Neupane K, van den Eeden SJ, Vary JC Jr, Peterson GJ, Wells RD, Geluk A, Hagge DA, Hawn TR.

PLoS Negl Trop Dis. 2014 Nov 20;8(11):e3263. doi: 10.1371/journal.pntd.0003263. eCollection 2014.

35.

Innovative Strategies to Identify M. tuberculosis Antigens and Epitopes Using Genome-Wide Analyses.

Geluk A, van Meijgaarden KE, Joosten SA, Commandeur S, Ottenhoff TH.

Front Immunol. 2014 Jun 25;5:256. doi: 10.3389/fimmu.2014.00256. eCollection 2014. Review.

36.

Clonal analysis of the T-cell response to in vivo expressed Mycobacterium tuberculosis protein Rv2034, using a CD154 expression based T-cell cloning method.

Commandeur S, Coppola M, Dijkman K, Friggen AH, van Meijgaarden KE, van den Eeden SJ, Wilson L, van der Ploeg-van Schip JJ, Franken KL, Geluk A, Ottenhoff TH.

PLoS One. 2014 Jun 6;9(6):e99203. doi: 10.1371/journal.pone.0099203. eCollection 2014.

37.

The in vivo expressed Mycobacterium tuberculosis (IVE-TB) antigen Rv2034 induces CD4⁺ T-cells that protect against pulmonary infection in HLA-DR transgenic mice and guinea pigs.

Commandeur S, van den Eeden SJ, Dijkman K, Clark SO, van Meijgaarden KE, Wilson L, Franken KL, Williams A, Christensen D, Ottenhoff TH, Geluk A.

Vaccine. 2014 Jun 17;32(29):3580-8. doi: 10.1016/j.vaccine.2014.05.005. Epub 2014 May 14.

PMID:
24837764
38.

Field-evaluation of a new lateral flow assay for detection of cellular and humoral immunity against Mycobacterium leprae.

Bobosha K, Tjon Kon Fat EM, van den Eeden SJ, Bekele Y, van der Ploeg-van Schip JJ, de Dood CJ, Dijkman K, Franken KL, Wilson L, Aseffa A, Spencer JS, Ottenhoff TH, Corstjens PL, Geluk A.

PLoS Negl Trop Dis. 2014 May 8;8(5):e2845. doi: 10.1371/journal.pntd.0002845. eCollection 2014 May.

39.

T-cell regulation in lepromatous leprosy.

Bobosha K, Wilson L, van Meijgaarden KE, Bekele Y, Zewdie M, van der Ploeg-van Schip JJ, Abebe M, Hussein J, Khadge S, Neupane KD, Hagge DA, Jordanova ES, Aseffa A, Ottenhoff TH, Geluk A.

PLoS Negl Trop Dis. 2014 Apr 10;8(4):e2773. doi: 10.1371/journal.pntd.0002773. eCollection 2014 Apr.

40.

Functional characterization of ocular-derived human alphaherpesvirus cross-reactive CD4 T cells.

Ouwendijk WJ, Geluk A, Smits SL, Getu S, Osterhaus AD, Verjans GM.

J Immunol. 2014 Apr 15;192(8):3730-9. doi: 10.4049/jimmunol.1302307. Epub 2014 Mar 12.

41.

Longitudinal immune responses and gene expression profiles in type 1 leprosy reactions.

Geluk A, van Meijgaarden KE, Wilson L, Bobosha K, van der Ploeg-van Schip JJ, van den Eeden SJ, Quinten E, Dijkman K, Franken KL, Haisma EM, Haks MC, van Hees CL, Ottenhoff TH.

J Clin Immunol. 2014 Feb;34(2):245-55. doi: 10.1007/s10875-013-9979-x. Epub 2013 Dec 27.

PMID:
24370984
42.
43.

Biomarkers for leprosy: would you prefer T (cells)?

Geluk A.

Lepr Rev. 2013 Mar;84(1):3-12. Review.

PMID:
23741878
44.

Challenges in immunodiagnostic tests for leprosy.

Geluk A.

Expert Opin Med Diagn. 2013 May;7(3):265-74. doi: 10.1517/17530059.2013.786039. Epub 2013 Mar 28. Review.

PMID:
23537134
45.

An unbiased genome-wide Mycobacterium tuberculosis gene expression approach to discover antigens targeted by human T cells expressed during pulmonary infection.

Commandeur S, van Meijgaarden KE, Prins C, Pichugin AV, Dijkman K, van den Eeden SJ, Friggen AH, Franken KL, Dolganov G, Kramnik I, Schoolnik GK, Oftung F, Korsvold GE, Geluk A, Ottenhoff TH.

J Immunol. 2013 Feb 15;190(4):1659-71. doi: 10.4049/jimmunol.1201593. Epub 2013 Jan 14.

46.

Mycobacterium leprae virulence-associated peptides are indicators of exposure to M. leprae in Brazil, Ethiopia and Nepal.

Bobosha K, Tang ST, van der Ploeg-van Schip JJ, Bekele Y, Martins MV, Lund O, Franken KL, Khadge S, Pontes MA, Gonçalves Hde S, Hussien J, Thapa P, Kunwar CB, Hagge DA, Aseffa A, Pessolani MC, Pereira GM, Ottenhoff TH, Geluk A.

Mem Inst Oswaldo Cruz. 2012 Dec;107 Suppl 1:112-23.

47.

Identification of serological biomarkers of infection, disease progression and treatment efficacy for leprosy.

Spencer JS, Duthie MS, Geluk A, Balagon MF, Kim HJ, Wheat WH, Chatterjee D, Jackson M, Li W, Kurihara JN, Maghanoy A, Mallari I, Saunderson P, Brennan PJ, Dockrell HM.

Mem Inst Oswaldo Cruz. 2012 Dec;107 Suppl 1:79-89.

48.

A multistage-polyepitope vaccine protects against Mycobacterium tuberculosis infection in HLA-DR3 transgenic mice.

Geluk A, van den Eeden SJ, van Meijgaarden KE, Dijkman K, Franken KL, Ottenhoff TH.

Vaccine. 2012 Dec 14;30(52):7513-21. doi: 10.1016/j.vaccine.2012.10.045. Epub 2012 Oct 24.

PMID:
23103299
49.

Alternative peptide repertoire of HLA-E reveals a binding motif that is strikingly similar to HLA-A2.

Lampen MH, Hassan C, Sluijter M, Geluk A, Dijkman K, Tjon JM, de Ru AH, van der Burg SH, van Veelen PA, van Hall T.

Mol Immunol. 2013 Jan;53(1-2):126-31. doi: 10.1016/j.molimm.2012.07.009. Epub 2012 Aug 13.

PMID:
22898188
50.

Pathogen-specific epitopes as epidemiological tools for defining the magnitude of Mycobacterium leprae transmission in areas endemic for leprosy.

Martins MV, Guimarães MM, Spencer JS, Hacker MA, Costa LS, Carvalho FM, Geluk A, van der Ploeg-van Schip JJ, Pontes MA, Gonçalves HS, de Morais JP, Bandeira TJ, Pessolani MC, Brennan PJ, Pereira GM.

PLoS Negl Trop Dis. 2012;6(4):e1616. doi: 10.1371/journal.pntd.0001616. Epub 2012 Apr 24.

Supplemental Content

Support Center